TNF and rheumatoid arthritis: Importantly, the cardiovascular safety of JAKi has recently come under scrutiny following the ORAL Surveillance trial, which reported an increased risk of major adverse cardiovascular events with tofacitinib compared to TNF inhibitors in patients with RA and cardiovascular risk factors [18].